Figure 5

Involvement of the NF-κB pathway in LPS-activated BV-2 cells. A, BV-2 cells in 24-well plates were treated with LPS (1 μg/ml) for 6 hr in the presence of CAY10470 (20 nM), an NF-κB inhibitor. Cell lysates were subjected to western blot analysis with antibodies against iNOS and β-actin. A representative experiment of three that were performed is shown. B, BV-2 cells in 96-well plates were transiently transfected with Luc-reporter gene with NF-κB promoter for 24 hr and then treated with LPS (1 μg/ml) for 3 hr in the presence of PKC or MAPK inhibitors. Luminescence from the cells was evaluated with a luciferase reporter assay system. RLUs (relative luminescence units) reflect the activity of NF-κB. U stands for U0126, and SB stands for SB203580. **, p < 0.01 were obtained when the drug-treated groups were compared to the LPS alone group. A representative experiment of four that were performed is shown.